Normogonadotropic ovarian insufficiency in adolescence (review of literature and clinical case)

Main Article Content

T.V. Sorokman
S.V. Sokolnyk
P.M. Moldovan
N.O. Popeliuk

Abstract

The objective of the review. Analysis of literature data related to the normogonadotropic ovarian insufficiency. Basic statements. The article presents a literature review and clinical case of normogonadotropic ovarian insufficiency in girls aged 16 years. The basic clinical-laboratory and genetic criteria are distinguished. We searched for published and unpublished studies using Pubmed as the search engine by the keywords: “normogonadotropic ovarian insufficiency”, “aromatase”, “molecular diagnosis”, “polycystic ovary syndrome”, “adolescents”, “clinical cases”, taking into consideration researches conducted for the last 15 years, citation review of relevant primary and review articles, conference abstracts, personal files, and contact with expert informants. The criterion for the selection of articles for the study was based on their close relevance to the topic, thus out of 256 analysed articles, the findings of the researchers covered in 34 articles were crucial. Because several features of polycystic ovary syndrome may be in evolution in adolescents, we suggest that only firm criteria should be used to make a diagnosis in adolescence: hyperandrogenism, oligomenorrhea and ovarian morphology. The most frequent clinical manifestations of aromatase deficiency of ovarian follicles are opsomenorrhea and androgen-dependent dermatopathy аnd genotype CYP19 ((TTTA)n polymorphism) — (TTTA)7(TTTA).

Article Details

How to Cite
Sorokman, T., S. Sokolnyk, P. Moldovan, and N. Popeliuk. “Normogonadotropic Ovarian Insufficiency in Adolescence (review of Literature and Clinical Case)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 5, Oct. 2017, pp. 366-73, doi:10.22141/2224-0721.13.5.2017.110027.
Section
Literature Review

References

National Collaborating Centre for Women’s and Children’s Health. Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press; 2004 Feb. PMID: 21089236.

Weiss RV, Clapauch R. Female infertility of endocrine origin. Arq Bras Endocrinol Metabol. 2014 Mar;58(2):144-52. doi: 10.1590/0004-2730000003021. PMID: 24830591.

Serhienko MYu, Yakovleva EB, Mironenko DM. Diagnosis and Treatment of Polycystic Ovary Syndrome in Pediatric Gynaecology. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2015;2(66):158-61. (in Russian).

Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The Polycystic Ovary Syndrome: An update on metabolic and hormonal mechanisms. J Med Life. 2015 Apr-Jun;8(2):142-5. PMID: 25866568.

Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014 Oct;127(10):912-9. doi: 10.1016/j.amjmed.2014.04.017.

Welt CK, DuranJM. The Genetics of Polycystic Ovary Syndrome. Semin Reprod Med. 2014 May; 32(3): 177-82. doi: 10.1055/s-0034-1371089.

Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol. 2013 Jul 5;373(1-2):29-38. doi: 10.1016/j.mce.2012.10.009.

Chen ZJ, Shi Y. Polycystic ovary syndrome. Front Med China. 2010 Sep;4(3):280-4. doi: 10.1007/s11684-010-0098-2.

Raicevic M, Saxena AK. Asynchronus bilateral ovarian torsions in girls-systematic review. World J Pediatr. 2017 Jun 22. doi: 10.1007/s12519-017-0052-3.

Azziz R, Dumesic D, Goodarzi M. Polycystic ovary syndrome: an ancient disorder? Fertil Steril. 2011 Apr;95(5):1544-8. doi: 10.1016/j.fertnstert.2010.09.032.

Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res. 2013;40:40-50. doi: 10.1159/000341840.

Carmina E, Oberfield SE, Lobo R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010 Sep;203(3):201.e1-5. doi: 10.1016/j.ajog.2010.03.008.

Ben-Shlomo I, Younis JS. Basic research in PCOS: are we reaching new frontiers? Reprod Biomed Online. 2014 Jun;28(6):669-83. doi: 10.1016/j.rbmo.2014.02.011.

Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone and polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013 Apr;28(4):1077-83. doi: 10.1093/humrep/det015.

Corbett S, Morin-Papunen L. The Polycystic Ovary Syndrome and recent human evolution. Mol Cell Endocrinol. 2013 Jul 5;373(1-2):39-50. doi: 10.1016/j.mce.2013.01.001.

Welt CK, Duran JM. Genetics of polycystic ovary syndrome. Semin Reprod Med. 2014 May;32(3):177-82. doi: 10.1055/s-0034-1371089.

Insenser M, Escobar-Morreale HF. Proteomics and polycystic ovary syndrome. Expert Rev Proteomics. 2013 Oct;10(5):435-47. doi: 10.1586/14789450.2013.837665.

Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 1997 Mar;6(3):397-402. PMID: 9147642.

Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015 Jan;145:213-25. doi: 10.1016/j.jsbmb.2014.06.003.

Mukherjee S, Shaikh N, Khavale S, et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol. 2009 May;160(5):855-62. doi: 10.1530/EJE-08-0932.

Ackerman CM, Garcia OA, Legro RS, Dunaif A, Urbanek M. SHBG (TAAAA)n Is Associated with Serum SHBG in a PCOS Case-Control Cohort. Endocr Rev. 2011;32:P2–66.03_Meeting Abstracts.

Ridderstrale M, Nilsson E. Type 2 diabetes candidate gene CAPN10: first, but not last. Curr Hypertens Rep. 2008 Feb;10(1):19-24. PMID: 18367022.

Nykolayenkov IP, Potin VV, Tarasova MA, et al. Ovarian aromatase activity in polycystic ovarial syndrome. Z akus zen bolezn. 2014;1(63):10-6. doi: 10.17816/JOWD63110-16. (in Russian).

Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009 Jun;30(4):343-75. doi: 10.1210/er.2008-0016.

Nothnick WB. The emerging use of aromatase inhibitors for endometriosis treatment. Reprod Biol Endocrinol. 2011 Jun 21;9:87. doi: 10.1186/1477-7827-9-87.

Demura M, Martin RM, Shozu M, et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum Mol Genet. 2007 Nov 1;16(21):2529-41. doi: 10.1093/hmg/ddm145.

Stocco C. Aromatase expression in the ovary: hormonal and molecular regulation. Steroids. 2008 May;73(5):473-87. doi: 10.1016/j.steroids.2008.01.017.

Silva JR, van den Hurk R, van Tol HT, Roelen BA, Figueiredo JR. Expression of growth differentiation factor 9 (GDF9), bone morphogenetic protein 15 (BMP15), and BMP receptors in the ovaries of goats. Mol Reprod Dev. 2005 Jan;70(1):11-9. doi: 10.1002/mrd.20127.

Elvin JA, Yan C, Wang P, Nishimori K, Matzuk MM. Molecular characterization of the follicle defects in the growth differentiation factor 9-deficient ovary. Mol Endocrinol. 1999 Jun;13(6):1018-34. doi: 10.1210/mend.13.6.0309.

Wu YG, Bennett J, Talla D, Stocco C. Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells. Mol Endocrinol. 2011 Apr;25(4):656-68. doi: 10.1210/me.2010-0367.

Mendelson CR, Jiang B, Shelton JM, Richardson JA, Hinshelwood MM. Transcriptional regulation of aromatase in placenta and ovary. J Steroid Biochem Mol Biol. 2005 May;95(1-5):25-33. doi: 10.1016/j.jsbmb.2005.04.016.

Gulbay G, Yesilada E, Celik O, Yologlu S. The Investigation of Polymorphisms in DNA Repair Genes (XRCC1, APE1 and XPD) in Women with Polycystic Ovary Syndrome. Asian Pac J Cancer Prev. 2017; 18(5): 1219-23. doi: 10.22034/APJCP.2017.18.5.1219.

Martin RM, Lin CJ, Nishi MY, et al. Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J Clin Endocrinol Metab. 2003 Jul;88(7):3027-34. doi: 10.1210/jc.2002-021780.

Czajka-Oraniec I, Simpson ER. Aromatase research and its clinical significance. Endokrynol Pol. 2010 Jan-Feb;61(1):126-34. PMID: 20205115.

Most read articles by the same author(s)

1 2 > >>